Ferdinandos Skoulidis

Incredibly proud of my daughter Isabella Skoulidis who summited M.Kilimanjaro to raise funds for children in Sudan. The climb has ended but the cause is more urgent than ever. #summitforSUDAN

Climbing for a Cause: Isabella’s Journey to Mount Kilimanjaro Summit for Sudan sapa-usa.org/summit-sudan/

Summit for Sudan | SAPA - Children in Sudan are facing a humanitarian crisis. SAPA,led by @YYElamin is providing life-saving aid. My 14-yo daughter is climbing M.Kilimanjaro to raise funds & awareness. Click the link below to support her journey.Thank you! sapa-usa.org/summit-for-sud…

Thrilled to share this exciting study ⁦@NatureMedicine⁩. Largest integrative analysis of #sotorasib efficacy biomarkers to date. Grateful to all co- investigators and the Amgen team for their hard work and most of all to our patients. ⁦@MDAndersonNews⁩ #KRAS #NSCLC

@CD_AACR @_hanielaraujo @XimoPechuan @MDAndersonNews Very proud of this work, now in print. Understanding RASi DTP programs is critical for improving outcomes with rational combinations. Thank you @_hanielaraujo, @XimoPechuan, Teng Zhou for the hard work and Elsa Quintana, Revolution Medicines for the wonderful collaboration

From the November issue: Mechanisms of Response and Tolerance to Active RAS Inhibition in KRAS-mutant NSCLC bit.ly/4einxFv @_hanielaraujo, @XimoPechuan, Teng Zhou, @FSkoulidis, and colleagues @MDAndersonNews

Key points: ✅CTLA4 abrogates KEAP1/STK11-related PD-(L)1i resistance in NSCLC ✅Dual ICB engages CD4+ TH1/reprograms myeloid cells ✅Validation in POSEIDON. Results support 1st line dual ICB+chemo for STK11/KEAP1 MUT NSCLC #STK11 #KEAP1 #CTLA4 #NSCLC nature.com/articles/s4158…

Excited to share our new study @Nature. Very grateful for the support of our collaborators, pharma and biotech partners and members of the Skoulidis and Heymach labs. Special thanks to star fellow @_hanielaraujo and @minhtruongdo. Thankful to our patients. @MDAndersonNews

Sotorasib for Lung Cancers with KRAS p.G12C Mutation | NEJM nejm.org/doi/full/10.10… #ASCO2021 #KRAS #MDAndersonNews #Sotorasib

A big thank you to all patients and their families, clinical trial personnel and colleagues for making the practice changing CodeBreaK100 clinical trial possible. #ASCO2021 #KRAS #MDAndersonNews #Sotorasib

Sotorasib for Lung Cancers with KRAS p.G12C Mutation | NEJM nejm.org/doi/full/10.10…

“The regulatory approval of sotorasib represents a major landmark for patients with KRAS G12C-mutated lung cancer,” says Dr. Ferdinandos Skoulidis of the now @FDA-approved targeted therapy drug that's helped trial participant Steve Castellaw. bit.ly/32REa9W #EndCancer

This seems like a good time to finally join twitter. On Friday 28th of May 2021 the FDA approved the first ever direct KRAS G12C inhibitor #sotorasib for patients with advanced KRAS p.G12C mutant lung cancer. After nearly 4 decades a truly historic milestone.